CBT-001有望成为全球首款用于治疗翼状胬肉的药物。 拨康视云 自主研发的 CBT-001 、 CBT-004 两款候选药物有望分别成为 翼状胬肉（一种良性增 生性眼表疾病）及血管化睑裂斑 的全球首创药物。包括上述两种适应症在内，诸多的眼科疾病 缺乏 针对性和高可及性的药物治疗选择，在全球范围内是一个巨大但未被满足的市场。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 据 IPO 早知道消息， 7 月 3 日， 拨康视云制药有限公司（下称 " 拨康视云 " ）正式以 "2592" 为股票代码在港交所主板挂牌上市。 此次上市，拨康视云 全球发售 6058.2 万股股份，香港公开 发行 占 20% ，国际发 行 占 80% 。 公开发行获 78.78 倍认购。 全球 发行 净 筹资 约 5.22 亿港元。 公司在本次发行中 引入 了 两名基石投资者，累计认购 2280 万美元（约 1.79 亿港元） 。 其中，知名天使投资人、企业家龚 虹嘉全资持有的富策控股认购 2000 万美元，瑞凯集团认购 280 万美元。 截至11:25，拨康视云报于每股7.27港元，市值超60亿港元。 拨康视 ...

Core Viewpoint - Shanxi Province is implementing several measures to promote high-quality development in the pharmaceutical and medical device industry through technological innovation and regulatory reforms [1] Group 1: Measures for Technological Innovation - The Shanxi Provincial Science and Technology Department has introduced six specific measures to support the research and innovation of pharmaceuticals and medical devices, including strengthening core technology research and accelerating drug development [1][2] - A total of 63 major special projects and key research plans have been initiated to address critical technology issues, with over 90 research platforms established to enhance collaborative innovation [2] Group 2: Talent and Funding Support - The Shanxi Provincial Science and Technology Department has recognized several innovative talent teams and appointed technology deputies to medical enterprises, providing essential talent support for core technology breakthroughs [2] - The government has allocated 69.11 million yuan in guiding funds, which has leveraged an additional 243.71 million yuan from social funds for technological innovation [2] Group 3: Innovation Incentives - A technology award subsidy program has been established to reward organizations and individuals contributing to technological innovation in the province [3] - High-tech enterprises that pass the recognition for the first time receive a reward of 100,000 yuan, while those that pass twice receive 200,000 yuan, reinforcing their role as innovation leaders [3]

Core Viewpoint - The legal opinion letter from Allbright Law Offices confirms that Zhejiang Dayang Biotechnology Group Co., Ltd. has fulfilled the necessary procedures and obtained the required approvals for its 2025 equity incentive plan, ensuring compliance with relevant laws and regulations [4][6][8]. Group 1: Approval and Authorization of the Incentive Plan - The company held its sixth board meeting on June 6, 2025, where it approved the draft of the 2025 equity incentive plan and related proposals, with related directors abstaining from voting [4]. - The sixth supervisory board meeting on the same day also approved the draft of the incentive plan and the list of proposed incentive recipients [5]. - The company publicly announced the list of incentive recipients from June 7 to June 16, 2025, with no objections raised by employees during the public notice period [5]. Group 2: Granting Date of the Incentive Plan - The granting date for the equity incentive plan was set for July 2, 2025, following the approval from the first extraordinary general meeting of shareholders on June 26, 2025 [6][7]. - The board confirmed that the granting date was within 60 trading days after the shareholders' meeting and complied with relevant regulations [7]. Group 3: Conditions for Granting the Incentive Plan - The granting conditions outlined in the incentive plan include that the company has not encountered any adverse audit opinions or significant financial issues [8]. - The proposed incentive recipients must not have faced any disqualifying circumstances, ensuring that all conditions for granting the incentive have been met [8]. Group 4: Conclusion of the Legal Opinion - The legal opinion concludes that the incentive plan's approval and authorization processes are legitimate and comply with the relevant laws and regulations, confirming the plan's validity [8].

苏州赛分科技股份有限公司 首次公开发行网下配售限售股份上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为2,975,050股。 ? 本次股票上市流通日期为2025 年 7 月 10 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2024 年 8 月 22 日出具的《关于同意苏州赛分科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2024〕1204 号），公司获准首次向社会公众公开发行人民币普通股（A 股）股票 4,997.5690 万股，并于 2025 年 1 月 10 日在上海证券交易所科创板上市。 公司首次公开发行股票完成后，总股本为 416,464,084 股，其中有限售条件流通 股 376,959,798 股，占公司总股本的 90.51%，无限售条件流通股 39,504,286 股， 占公司总股本的 9.49%。 本次上市流通的限售股为公司首次 ...

证券代码：300972 证券简称：万辰集团 公告编号：2025-049 福建万辰生物科技集团股份有限公司 关于 2023 年限制性股票激励计划第二个归属期（第一批次）及 次）归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示： 年限制性股票激励计划第二个归属期（第一批次）激励对象：10 人，2024 年限 制性股票激励计划首次授予部分第一个归属期（第一批次）激励对象：7 人） 量：453.3301 万股，2024 年限制性股票激励计划首次授予部分第一个归属期（第 一批次）拟归属数量：309.2000 万股） A 股普通股股票 根据福建万辰生物科技集团股份有限公司（以下简称"公司"或"万辰集团"） 于 2025 年 6 月 23 日召开的第四届董事会第二十七次会议和第四届监事会第二 十八次会议，分别审议通过了《关于公司 2023 年限制性股票激励计划第二个归 属期（第一批次）归属条件成就的议案》《关于公司 2024 年限制性股票激励计 划首次授予部分第一个归属期（第一批次）归属条件成就的议案》。近日公司办 理了 2023 年 ...

行业研究丨深度报告丨制药、生物科技与生命科学 [Table_Title] 以 IBI363 为鳍，一直游到海水变蓝 ——信达生物研发日专题 报告要点 [Table_Summary] 重磅一代 IO 疗法的核心专利序列预计集中在 2028-2032 年过期，MNC 对于延续/抢占下一代 肿瘤基石治疗药物市场的需求迫切。我们认为二代 IO 潜在市场规模巨大，市场总规模或将达 到 2000 亿美元。信达生物差异化使用 PD-1 单抗/IL-2 融合设计（顺式激活）以及α偏向性设 计, IBI363 在多个 IO 治疗耐药热肿瘤、冷肿瘤中显示出 Best-in-Class 的潜力。 %% %% %% %% research.95579.com 1 丨证券研究报告丨 分析师及联系人 [Table_Author] 彭英骐 刘长洪 SAC：S0490524030005 SFC：BUZ392 请阅读最后评级说明和重要声明 2 / 20 %% %% %% %% research.95579.com 2 制药、生物科技与生命科学 cjzqdt11111 [Table_Title 以 2] IBI363 为鳍，一直游到海水变蓝 — ...

Core Viewpoint - The CESHKB index has shown significant growth, with a year-to-date increase of 64.30%, indicating a strong performance in the biotechnology sector listed in Hong Kong [1][2]. Group 1: Index Performance - The CESHKB index opened high and fluctuated, closing at 7388.22 points with a trading volume of 12.985 billion [1]. - Over the past month, the CESHKB index has risen by 14.05%, and over the last three months, it has increased by 17.80% [1]. Group 2: Index Composition - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., reflecting the overall performance of biotechnology companies listed in Hong Kong [1]. - The top ten holdings in the CESHKB index include: - CanSino Biologics (10.49%) - Innovent Biologics (9.9%) - WuXi Biologics (9.73%) - 3SBio (8.86%) - BeiGene (8.81%) - Zai Lab (5.86%) - WuXi AppTec (5.85%) - Kelun-Biotech (5.1%) - Genscript Biotech (4.42%) - Ascentage Pharma-B (4.15%) [1]. Group 3: Market and Industry Overview - The CESHKB index is entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2].

Market Overview - Major industry ETFs in the US experienced a decline, with the global airline industry ETF down by 0.9%, the healthcare ETF down by 0.72%, and the utilities ETF down by 0.67% [1] Industry Performance - The global airline industry ETF is priced at $23.22, reflecting a decrease of $0.21 or 0.90% with a trading volume of 43,489 shares and a total market value of $73.14 million, showing an 8.40% decline year-to-date [2] - The healthcare ETF is priced at $135.73, down by $0.98 or 0.72%, with a trading volume of 676,100 shares and a total market value of $259.74 billion, indicating a year-to-date decrease of 0.48% [2] - The utilities ETF is priced at $81.39, down by $0.55 or 0.67%, with a trading volume of 942,700 shares and a total market value of $11.81 billion, reflecting a year-to-date increase of 9.05% [2] - The financial sector ETF is priced at $52.48, down by $0.18 or 0.34%, with a trading volume of 2.23 million shares and a total market value of $584.13 billion, showing a year-to-date increase of 9.35% [2] - The technology sector ETF is priced at $250.50, down by $0.47 or 0.19%, with a trading volume of 254,600 shares and a total market value of $796.73 billion, indicating a year-to-date increase of 8.10% [2] - The energy sector ETF is priced at $85.78, up by $0.32 or 0.37%, with a trading volume of 1.09 million shares and a total market value of $21.48 billion, reflecting a year-to-date increase of 1.74% [2]

信息科技及电信服务、医疗和医药、以及零售、消费品及服务相关的行业板块将会是市场焦点。 具体看来，上半年香港市场共有44只新股上市，其中42只在主板上市，主板新股以零售、消费品及服务 为主，占比为34%，其次为工业及材料与医疗和医药，各占23%。 普华永道预计，下半年，预期利好市场气氛将延续。目前，已经递交申请在香港上市的企业超过200 家，涵盖制造业、零售等传统行业，也有生物科技、医疗、人工智能等新经济行业，以及大型A股龙头 企业、中概股及海外企业亦积极赴港集资。 普华永道香港资本市场服务合伙人梁令欣认为，尽管地缘冲突、贸易关税等不确定因素依然存在，香港 IPO市场仍展现出明显的增长趋势，预计今年的新股市场将迎来近四年来最活跃的募资潮。 梁令欣提到，截至2024年12月，港交所在第18C章下有3家特专科技公司，在第18A章下则有67家生物科 技公司。2025年5月推出"科企专线"后，生物技术与制药产业受益显著，到2025年6月，生物科技公司的 上市量增至73家。此外，人工智能、信息科技和电信产业是另一个主要的成长领域。长期来看，创新医 疗保健和科技公司的比例将会进一步提高。 普华永道预测，2025全年将有90 ...

mRNA 平台开发稳步推进，可逆 BTK 膜性肾病数据优异；上调目标价 | 买入 | | | | --- | --- | --- | | 1 | 年股价表现 | | | 250% | 1952 HK | 恒生指数 | | 200% | | | | 150% | | | | 100% | | | | 50% | | | | 0% -50% | | | 股份资料 交银国际研究 公司更新 | 医药 | 收盘价 | 目标价 | 潜在涨幅 | 2025 年 7 月 2 日 | | --- | --- | --- | --- | --- | | 62.20 | 港元 | 港元 72.50↑ | +16.6% | | | 云顶新耀 (1952 HK) | | | | | | 52周高位 (港元) | 65.15 | | --- | --- | | 52周低位 (港元) | 18.28 | | 市值 (百万港元) | 20,198.83 | | 日均成交量 (百万) | 13.36 | | 年初至今变化 (%) | 28.51 | | 200天平均价 (港元) | 47.94 | | 资料来源 : FactSet | | 丁 ...